FY2024 Earnings Estimate for Theratechnologies Inc. (TSE:TH) Issued By Cantor Fitzgerald

Theratechnologies Inc. (TSE:TH) – Equities research analysts at Cantor Fitzgerald raised their FY2024 EPS estimates for Theratechnologies in a report issued on Thursday, April 11th. Cantor Fitzgerald analyst L. Chen now expects that the company will earn $0.00 per share for the year, up from their prior forecast of ($0.08). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Theratechnologies’ current full-year earnings is $0.04 per share.

Theratechnologies Trading Down 4.8 %

TSE TH opened at C$1.80 on Monday. The company has a fifty day simple moving average of C$1.99 and a two-hundred day simple moving average of C$2.11. The stock has a market cap of C$82.76 million, a P/E ratio of -1.45, a P/E/G ratio of -8.50 and a beta of 1.73. Theratechnologies has a 12-month low of C$1.22 and a 12-month high of C$5.84. The company has a current ratio of 1.34, a quick ratio of 0.64 and a debt-to-equity ratio of 562.07.

Theratechnologies (TSE:TH) last posted its quarterly earnings results on Wednesday, February 21st. The company reported C($0.11) earnings per share (EPS) for the quarter. The company had revenue of C$31.93 million during the quarter. Theratechnologies had a negative return on equity of 1,116.86% and a negative net margin of 29.30%.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.